A new study has added mental health risks associated with a section of drugs called GLP-1 receptor agonists, which is usually prescribed for type 2 diabetes.

GLP-1 receptor agonists are drugs that help in low blood sugar. They work by mimicking a natural hormone in the body that controls blood sugar and appetite. These drugs slow down digestion, help the body release the right amount of insulin, and make people feel full for a long time.

Initially it was developed to manage blood sugar levels in diabetic patients, GLP -1 agonists have gained popularity for their weight loss effects.

Many popular drugs, such as ozmpic and mounjaro, contain compounds such as semaglutides and tirzepetides, which are part of the GLP -1 receptor agonist class.

While these drugs have shown the effects of weight loss, the study shows that they can affect some of depression related genes.

Conclusions increase serious concerns about the safety of these drugs for some people, especially with specific genetic symptoms.

The study consisted of 24 researchers from institutions in the United States, Brazil, Iran and Israel, who examined individuals with hypodopaminargia, a condition that was characterized by low dopamine activity in the brain. Dopamine is a neurotransmitter in mood regulation, motivation and reward processing.

Using pharmacogenomic analysis, researchers examined the interaction between GLP-1 receptor agonists and genes associated with dopamine signaling including DRD3, BDNF and Creb1.

Conclusions indicate that GLP-1 receptor agonists may disrupt dopamine balance in some individuals, especially with problems already existing in the dopamine system. This disruption may increase the risk of depression, anxiety and suicidal thoughts.

Study experts have warned that mental health risks associated with these drugs should not be ignored. Senior writer Dr. Kenneth Blum emphasized the need to carefully determine. “We urge the clinical prescribed community to ‘move with caution to avoid another tragic wave of people who die to lose weight,” “

The co-writer of the study, Dr. Mark S. Gold said that health authorities such as US Food and Drug Administration (FDA) and European Medicine Agency (EMA) should consider updating the warning label on these drugs to reflect new conclusions.

The European Medicine Agency has already started reviewing the security of GLP -1 receptor agonist after an increase in reports of psychiatric side effects.

In response, the authors of the study recommend more individual approaches to determine these drugs. This may include genetic testing to help identify individuals that may be at greater risk.

Although these drugs remain effective for managing weight and blood sugar levels, researchers highlighted the importance of regular mental health check -up.